The European Federation for Medicinal Chemistry (EFMC) is an independent association representing medicinal chemistry societies in Europe. Its objective is to advance the science of medicinal chemistry by promoting cooperation and networking, by providing training and mentoring, by rewarding scientific excellence, and by facilitating communication and influencing stakeholders.

Meetings  May 2016 Next

STOA Working Breakfast - Solving Antimicrobial Resistance

During the STOA Working Breakfast co-organised by the European Parliament´s STOA, EuCheMS, and EFMC on the 28 April 2016, researchers and several Members of the European Parliament analysed the global challenge of antimicrobial resistance and weighted the pros and cons of possible solutions.

Antimicrobial Resistance (AMR) is the ability of microorganisms to withstand attack by antimicrobial drugs such as antibiotics, antifungal or antivirals, and is a serious issue that threatens to render many of the treatments we use today ineffective in the future – from tuberculosis to HIV, from pneumonia to other common infections.

The STOA Working Breakfast was an outcome of the work of the EFMC Working group on “Influence on European science policy”, chaired by Anders Karlén, in collaboration with EuCheMS.

(please note that the outcomes will also soon be available at STOA´s website)

Workshop Outcomes – Forward Look

This workshop attracted a capacity audience including at least six MEPs. It was chaired by Paul Rübig MEP, Chair of STOA.

Clear recommendations emerged from the Workshop. These include:

  • Antimicrobial resistance, of which antibiotic resistance is a subset, is a current problem in Europe that could become much worse; it is an even more serious problem in developing countries.
  • Better use of current antimicrobials is essential. This should include:
    • Enforcement of the ban on using antimicrobials in agriculture for anything other than treating disease
    • A major advertising campaign to ensure prescribed doses of antimicrobials are taken to completion
    • Better diagnostics to help doctors identify the correct antimicrobial to use
    • Ensuring that all doctors know when antimicrobial treatment is required
  • In addition to the better use of current antimicrobials, novel antimicrobials are urgently needed to treat multiresistant microbes.
  • Pharmaceutical companies will not, on their own, tackle antimicrobial resistance, because there is presently a predicted negative return on investment for a new antimicrobial drug.
  • Antimicrobial resistance should not be considered as a problem to be addressed in isolation, but in conjunction with efforts to address other medical problems of major European concern that are currently not tackled effectively, including e.g. ageing related and psychiatric diseases.
  • There is thus an urgent need for a consortium to be created involving pharmaceutical companies, philanthropists, the EC, and national governments to provide leadership and funding to tackle this problem. This consortium should:
    • Set up 1-3 major focused hubs for medicinal chemistry research in fields including antibacterial/antimicrobial/anti-infective development. The centres should tackle several disease areas in order to ensure continuity of funding and critical mass of activity. Specialist activities, e.g. high throughput screening / crystallography could be carried out in well linked spokes, not necessarily within the hubs
    • in the area of new antimicrobials,
      • principally focus on classes of clinically validated antimicrobials and/or on clinically validated targets
      • be fully equipped for drug discovery and development, mechanistic studies and testing against clinical isolates
      • be equipped to perform in vitro ADMET, in vivo pharmacology and efficacy and DMPK studies either by in house or external capabilities
      • be able to provide leadership in terms of in vitro and in vivo pharmacology, pharmacodynamics, distribution, metabolism and formulation
      • be linked to excellent centres for fundamental research which should also be funded properly
      • be linked to excellent hospitals with research & teaching facilities
      • be able to have access to large populations with microbial infections for significant clinical trials, ideally locally or by partnership
    • fund innovative ideas in key areas wherever they arise
    • link all researchers in the field so that they share all results immediately they are available
    • ensure that some of their research is not hampered by patents and lawyers
  • Such a development is a natural evolution of world leading collaborative activities in Europe. It will cost in excess of €1 bn to fund each centre and its associated researchers.

Presentations:

Solving antibiotic resistance: an introductionDavid Cole-Hamilton, EuCheMS President

Making choices on antibiotics (presentation to be uploaded soon) – Chris Schofield, University of Oxford

What it there are no new antibiotics?Lloyd Czaplewski, Chemical Biology Ventures Ltd


EFMC Awards 2016

The EFMC is pleased to announce the recipients of the 2016 Awards:

  • Nauta Award for Pharmacochemistry
    Prof. François Diederich – ETH Zürich, Switzerland
  • UCB-Ehrlich Award for Excellence in Medicinal Chemistry
    Dr Paul J. Hergentrother – University of Illinois at Urbana-Champaign, United States
  • Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery
    Prof. Jan Steyaert – VU Brussels, Belgium

The Awards will be presented during the XXIV International Symposium on Medicinal Chemistry (EFMC-ISMC 2016), scheduled to be held on August 28 – September 1, 2016 in Manchester, United Kingdom.


EFMC Prizes 2016

The Selection Committees are proud to announce the names of the winner and the most meritorious runners-up of the EFMC Prize for a Young Medicinal Chemist in Industry and the EFMC Prize for a Young Medicinal Chemist in Academia.

EFMC PRIZE FOR A YOUNG MEDICINAL CHEMIST IN INDUSTRY

Jean Quancard (Novartis Pharma, Switzerland)
Nicolas Desroy (Galapagos, France)
Anne Valade (UCB, Begium)

EFMC PRIZE FOR A YOUNG MEDICINAL CHEMIST IN ACADEMIA

Frank Boeckler (Eberhard Karls University Tuebingen, Germany)
Nathaniel Martin (Utrecht University, The Netherlands)
Sylvia Ortega Gutierrez (Universidad Complutense de Madrid, Spain)

The EFMC Prizes Ceremony will take place during the XXIV EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2016) in Manchester, UK, on August 28-September 1, 2016. Dr Jean Quancard and Prof. Frank Boeckler will be invited to give an Oral Communication during the Symposium.


XXIV EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2016)

August 28 - September 1, 2016 - Manchester, United Kingdom

The XXIV EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2016) will be organised by the Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry, on behalf of the European Federation for Medicinal Chemistry (EFMC).

For more information please visit EFMC-ISMC 2016

Organised by : European Federation for Medicinal Chemistry (EFMC)
Organised by : The Biological and Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry (RSC) (United Kingdom)


3rd EFMC Young Medicinal Chemist Symposium (EFMC-YMCS)

The EFMC Young Medicinal Chemist Symposium is an initiative of the European Federation for Medicinal Chemistry (EFMC). After a succesful first edition organised in Lisbon in September 2014 and a second edition organised in Antwerp in September 2015, the third edition will be organised in connection with XXIV EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2016), and will take place in Manchester (United Kingdom) on September 1-2, 2016.

This short symposium has the aim of:

  • Creating a network of young European investigators in Medicinal Chemistry
  • Stimulating young European investigators in Medicinal Chemistry to share their scientific work with peers and inspiring leaders in the field
  • Creating competition and excellence in Medicinal Chemistry within Europe by selecting the European Champion in Medicinal Chemistry

For more information please visit www.efmc-ymcs.org


MedChemComm

What are your colleagues reading in MedChemComm? Find out more here: Most read articles !


M T W T F S S
25 26 27 28 29 30 01
02 03 04 05 06 07 08
09 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31 01 02 03 04 05
All events   |  Future events

Job portal

There are currently no jobs available

Job portal page

Follow us on Twitter

Follow us on LinkedIn

ChemBridgeBoehringer IngelheimNovartisProf Dr W. Th. Nauta FoundationPfizerServierRoche
 Prous Institute for Biomedical ResearchUCBJanssen R&DBayerMerck